Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829 is registered in ClinicalTrials.gov with Sobi, Inc. as lead sponsor.

NCT NCT04638829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04638829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
Lead sponsor
Sobi, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 15, 2021
Completion date
January 3, 2024
Enrollment
60 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia